Clinical and Economic Impact of Malnutrition Per Se on the Postoperative Course of Colorectal Cancer Patients
Authors
Affiliations
Background & Aims: To assess the medico-economic impact of malnutrition in patients who underwent surgery for colorectal cancer.
Methods: We performed post-hoc analyses of data from the Alves et al. prospective study. Using standard criteria of malnutrition, 2 groups were created a posteriori: Well-nourished (WN) and Mal-nourished (MN) patients. The 2 groups were statistically adjusted for age, cancer status, and scheduled surgery. Individual costs were valued using the French National Cost Study. Postoperative morbidity, mortality, hospital length-of-stay (LOS), and discharge setting were compared. We defined 3 scenarios, the most accurate estimate and its upper and lower limits, to assess the economic impact of malnutrition.
Results: 453 patients were included in the analyses. Complication and mortality rates were not significantly different between the 2 groups. MN patients had a mean LOS 3.41 days significantly longer than WN patients (p = 0.017). In MN patients, the cost of hospital stay was increased by around 3360 €, creating an annual impact of 10,159,436 € for French non-profit hospitals.
Conclusions: Malnutrition in colorectal cancer surgical patients is associated with an increased LOS resulting in significant budget impact. Further studies are needed to investigate this impact and the related cost-benefit of perioperative specialized nutritional support and implementation of the ERAS protocol in this homogeneous category of patients.
McLay K, Stonewall N, Forbes L, Peters C J Patient Rep Outcomes. 2024; 8(1):71.
PMID: 38995461 PMC: 11245459. DOI: 10.1186/s41687-024-00750-8.
Nutritional Assessment Tools for Patients with Cancer: A Narrative Review.
Wang P, Soh K, Khazaai H, Ning C, Huang X, Yu J Curr Med Sci. 2024; 44(1):71-80.
PMID: 38289530 DOI: 10.1007/s11596-023-2808-4.
Xie H, Wei L, Liu M, Liang Y, Yuan G, Gao S BMC Cancer. 2022; 22(1):1316.
PMID: 36522702 PMC: 9756500. DOI: 10.1186/s12885-022-10405-w.
Schuetz P, Sulo S, Walzer S, Krenberger S, Brunton C Front Oncol. 2022; 12:916073.
PMID: 36016618 PMC: 9396738. DOI: 10.3389/fonc.2022.916073.
Greathouse K, Wyatt M, Johnson A, Toy E, Khan J, Dunn K Neoplasia. 2022; 29:100800.
PMID: 35500546 PMC: 9065883. DOI: 10.1016/j.neo.2022.100800.